A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
ASHG President Urges Focus on Penetrance, Expressivity for Genetics-Driven Precision Medicine
Premium
In his presidential address, delivered to a packed auditorium on Tuesday, Bruce Gelb acknowledged that this year's event is being somewhat overshadowed by the US presidential election.
Lung Cancer Study Suggests Concurrent RNA, DNA Testing Picks up Actionable SVs
RNA sequencing unearthed actionable structural variants missed with DNA-only sequencing based on tumor assays on 5,570 advanced non-small cell lung cancer cases.
Exact Sciences Stock Tumbles After Firm Lowers Full-Year Revenue Guidance, Misses Q3 Estimates
The company's CEO said that results and resulting downward adjustment of its full-year guidance don't reflect its true potential, citing plans to do better in 2025.
Illumina Q3 Revenues Fall 3 Percent on Weak Instrument Sales
The company lowered its full-year revenue guidance for the second time this year, but upped EPS guidance, as macroeconomic headwinds dinged Q3 results.
After years of persistence, genetic counselors at UT Southwestern got BCBS of Texas to fix a system error that was leading to payment denials for services.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
NeoGenomics Q3 Revenues up 10 Percent
The company attributed the growth to a rise in both test volume and revenue per test, despite slagging sales in its advanced diagnostics arm.